Increase of HDL-cholesterol and Decrease of TG Levels with Pitavastatin after Switching from Atorvastatin in Patients with Type 2 Diabetes Mellitus
|
Accession number;06A0093610
|
| Title;Increase of HDL-cholesterol and Decrease of TG Levels with Pitavastatin after Switching from Atorvastatin in Patients with Type 2 Diabetes Mellitus |
| Author;
KUTOH EIJI
(Bmc, Beerse, Bel)
|
Journal Title;Ther Res
|
Journal Code:Y0681A
|
ISSN:0289-8020
|
|
VOL.27;NO.1;PAGE.121-126(2006)
|
| Figure&Table&Reference;FIG.3, TBL.1, REF.23 |
| Pub. Country;Japan |
| Language;English |
| Abstract;Pitavastatin is a novel statin which was developed and has been available in Japan since 2003. In our daily clinical practice, only limited evidence exists regarding its efficacy and safety in comparison to other statins. In order to make a direct comparison of the efficacy between pitavastatin and other statins (e.g. atorvastatin) in patients with type 2 diabetes, the following study was undertaken. Randomly selected 22 patients with type 2 diabetes who were receiving 5 or 10 mg of atorvastatin were switched to receive 1 or 2 mg of pitavastatin, respectively. At 3 months, the levels of T-C, LDL-C, HDL-C, TG and HbA1C levels were compared with those at baseline. 1) significant reductions of T-C (-8.5%, 235.+-.50 mg/dL vs. 215.+-.35 mg/dL,p=0.035705) and TG (-20.4%, 191.+-.84 mg/dL vs. 152.+-.70 mg/dL, p=0.02991) levels were observed. 2) reductions of LDL-C (-10.9%, 146.+-.53 mg/dL vs. 130.+-.28 mg/dL, p=0.098439) levels were observed without reaching statistically significant differences. 3) significant increase of HDL-C (+5.7%, 52+13 mg/dL vs. 55.+-.14 mg/dL, p=0.0198) levels were observed. With respect to its safety, no particular side effects on liver, kidney or muscle were observed as assessed by the biochemical analysis of the blood. Taken together, these results suggest that pitavastatin at doses of 1-2mg/day is safe and has favorable effects on dyslipidemia in patients with type 2 diabetes in comparison to atorvastatin at doses of 5-10mg/day. (author abst.) |
|
|
|
Related Articles;
|
|
